Reference number : 276-2011-2012-Q2-00249, amendment number : , agreement type : C, recipient legal name : ImmunoVaccine Technologies Inc.|ImmunoVaccine Technologies Inc., recipient country : CA, recipient province : NS, recipient city : Halifax|Halifax, recipient postal code : B3H 0A8, program name english : Atlantic Innovation Fund (AIF) - II, program name french : Fonds d'innovation de l'Atlantique (FIA) - II, program purpose english : nan, program purpose french : nan, agreement title english : 197861, agreement title french : 197861, agreement number : 197861, agreement value : 2944000.0, agreement start date : 2011-09-15, agreement end date : 2013-08-31, description english : Development of  DepoVax-based cancer immunotherapies, description french : Mise au point d'immunothérapies à base de DepoVax pour traiter le cancer, expected results english : nan, expected results french : nan, additional information english : The assistance type is Conditionally Repayable Contribution., additional information french : Le type d'aide est Contribution à remboursement conditionnel., owner organization : acoa-apeca, owner organization title : Atlantic Canada Opportunities Agency | Agence de promotion économique du Canada atlantique